Considerably undervalued. New Management/strategy is the right one. Expect EPS over $.35 for 07. Stock could go to $20. Last two Q's over 30% organic growth on retained biz. Hyper growth continues esp internationally and based on click fraud product

Despite PFE woes, Exubera will take center stage. Expect rapid growth in scripts esp once DTC ads start in 2nd half. Could be profitable by Q4, but more likely early next year. Next generation bong to leapfrog comp. Cheap stock/takeover potential

Another delivery name, will garner positive emotion as it marches toward its own inhaled insulin. Many products under development, many relationships w/majors. Good balance sheet. Cheap stock. Recent Q is cathartic

Strong pipe and product set. Solid financials. Stock done nothing for last year since they surprise hiked R&D. Now beginning to see fruits of labors. Nice growth/profits/cashflow. Cheap stock

I expect takeover here. Probably by Biogen. But buying based on cheapness, good growth, overreaction to competitive threat. 3 product label expansions/new approvals in '06. Solid growth, profits.

Expect takeover soon. Good growth but slashed R&D to pretty up for sale. Profitable. Excellent Fuzion sales yr 1. Strong partner